3665 PLATO ACT 4: Long term results of an RCT evaluating reduced dose and standard dose chemoradiotherapy in early-stage anal cancer (ISRCTN:88455282)
David Sebag‐Montefiore(University of Leeds), Richard Adams(Velindre Cancer Centre), Natalie L. Abbott(St Bartholomew's Hospital), Joanne Copeland(University of Leeds), M. Hawkins(University College Hospital), Susan D. Richman(University of Leeds), Alexandra Gilbert(St James's University Hospital), Vicky Goh(King's College London), Sarah Brown(University of Leeds), Duncan C. Gilbert(Royal Sussex County Hospital), R. Glynne‐Jones, Sheela Rao(Royal Marsden NHS Foundation Trust), Sharon Ruddock(University of Leeds), Joanne Webster(University of Leeds), Alexandra Smith(University of Leeds), Mark Harrison(Hillingdon Hospitals NHS Foundation Trust), Andrew G. Renehan(University of Manchester), R. Muirhead(Churchill Hospital), Lindy Berkman
Cited by 1
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
|The Lancet Oncology|2014|994